Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.07 | 0.12 | -0.73 |
| FCF Yield | -6.54% | -8.10% | -21.36% | -6.06% |
| EV / EBITDA | -11.35 | -28.16 | -6.28 | -14.90 |
| Quality | ||||
| ROIC | 10.37% | -15.35% | -53.00% | -52.13% |
| Gross Margin | 99.66% | 99.15% | 98.30% | 98.33% |
| Cash Conversion Ratio | 0.15 | 0.46 | 0.62 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.96% | 12.98% | 20.26% | 24.38% |
| Free Cash Flow Growth | 34.94% | 75.83% | 26.85% | 1.30% |
| Safety | ||||
| Net Debt / EBITDA | -4.57 | -13.27 | -2.44 | -1.59 |
| Interest Coverage | -3.19 | -1.02 | -4.51 | -7.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.08 | 0.50 |
| Cash Conversion Cycle | -5,245.57 | -2,087.08 | -6,341.06 | -855.92 |